Treatment of COVID-19 Patients Using Wharton’s Jelly-Mesenchymal Stem Cells
Bref résumé:Le but de cette étude est d’étudier l’utilisation potentielle des cellules souches mésenchymateuses Jelly de Wharton. (WJ-MSC) pour le traitement d'un patient diagnostiqué avec une infection par le virus Corona SARS-CoV-2, et présentant des symptômes du COVID-19.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Use ofCellules souches for COVID-19 Treatment | Biological: WJ-MSC | Phase 1 |
Description détaillée:
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.
Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.
